hydroxyurea + cytarabine + prednisone

hydroxyurea + cytarabine + prednisone is a combination of three drugs, each of which has distinct antineoplastic and immunomodulatory effects. Hydroxyurea is a ribonucleotide reductase inhibitor that targets DNA synthesis. Cytarabine is a cytosine nucleoside analog that inhibits DNA polymerase, disrupting DNA synthesis and repair. Prednisone is a synthetic glucocorticoid used for its anti-inflammatory and immunosuppressive properties. This drug combination may be used or studied in the context of treating hematologic malignancies, such as acute myeloid leukemia (AML) and lymphomas, though its use is less well-documented as a fixed combination. Each component has established roles in chemotherapy regimens, and the rationale for combining hydroxyurea and cytarabine includes overcoming resistance to cytarabine via inhibition of SAMHD1, while prednisone is added for its anti-inflammatory and cytotoxic activities in certain leukemias or lymphomas[1][2][3][6][7].